RE:RE:This has some people very nervous:ZoranSto wrote: APRIL 2023 and we are trading at 60 cents.....proph you set yourself up for that one....
I think you are the only one left supporting Gilles....maybe he is related to you...we will never know. As you can tell by the various posters and the shareprice we have all had enough. Bring on the AGM.
Z
ZoranSto, with the TSX-Venture down approximately 39% in 2022 and CZO only down about 3% what rational basis do you have to be so hard on CZO's stock performance?
Have you been the victim of a defamation campaign against Gilles, its Board of Directors, and the company?
CZO actually won an award from the TSX-Venture for 2022 based on stock price performance, market cap gain, and volume as has been noted. CZO was recognized as one of the top 50 on the TSX-V and in the top ten in life sciences in 2022. We have been in the worst biotech bear market in history. CZO proved itself as a safe haven during the historic market chaos.
During 2022 CZO also signed the deal with C$20 billion market cap Symrise validating the base business which had another year of record sales. Growth was approximately double digit consistent with CZO's growth rate of the last decade. Cash grew to $13 million with no debt providing a cash runway for the next strategic milestones for its pipeline. The President and CEO of the Canadian division of the largest biotech in the world joined CZO's Board and became Chairman validating CZO's strategic position and long-term growth prospects. It is virtually impossible to find someone more qualified in biotech in Canada to join the comapny. Dr. Ask experessed his excitement concerning the fibrosis program and was hired by the second largest pharma in the world as Director of Translational Medicine. The noted Dr. Kolb was added to CZO's program and he has clinical trial experience as CZO prepares its go-no go trial decision for the second half of this year. CZO's CoQ10 bioavailability data blew the industry gold standard out of the water and suggests CZO has found a way to harness the delivery capability of macrophages. CZO announced and took steps to scale-up PGX. The avenanthramide clinical trial was approved by Health Canada for a clinical trial program through to indications of efficacy.
One what rational basis can you be upset with CZO's performace as outlined above. It has been exceptional. Again, have you been the victim of a defamation campaign against this company?